NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NovaSterilis

NovaSterilis

Private
Lansing, New YorkHealthcare & Life Scienceshttps://novasterilis.com/

Last Round

Grant

Feb 1, 2024

Total Funding Raised

$7.39M

Company Overview

NovaSterilis is a biotechnology company that develops and manufactures supercritical carbon dioxide (scCO2) sterilization and decellularization technology platforms for the regenerative medicine, medical device, and pharmaceutical industries.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Medical Devices, Biotechnology, Clean Manufacturing

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Usage-Based SaaS

AI Layer

Non-AI

Keywords

supercritical CO2 sterilizationscCO2decellularizationsterility assurance levelSALbiotech equipmentterminal sterilizationgreen sterilizationmedical device sterilizationprocess validationregenerative medicinelow-temperature sterilizationclean manufacturingbiomaterial processingcontract sterilization

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NovaSterilis Comparables

Compare NovaSterilis with similar companies based on industry and business-model similarity.

NovaSterilis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Noxilizer
83%
Andersen Sterilizers, Inc.
74%
De Lama S.p.A.
69%

NovaSterilis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 1, 2024
GrantSep 20, 2022
GrantJan 18, 2017
GrantFeb 1, 2015
GrantSep 1, 2012
Grant
Sep 15, 2011

NovaSterilis Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 7, 2025

    Presenting at the 34th Annual Conference of the European Society for Biomaterials.

  • Feb 1, 2024

    $1.75M grant from National Institute of Allergy and Infectious Diseases.

NovaSterilis Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NovaSterilis Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NovaSterilis's valuation, stock price, and market status.

Firmographic Details

HeadquartersLansing, New York
Employee Range9
Year Founded2000
Last FundingFeb 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.